Li-Fu Li1, Zheng-Jie Wei1, Hong Sun1, Bo Jiang1. 1. Li-Fu Li, Zheng-Jie Wei, Hong Sun, Bo Jiang, Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China.
Abstract
AIM: To evaluate the effect of β-catenin immunohistochemical expression on the prognosis of gastric cancer (GC). METHODS: We searched Pubmed and Embase to identify eligible studies. The search ended on November 10, 2013, with no lower date limit. The citation lists associated with the studies were used to identify additional eligible studies. We included studies reporting sufficient information to estimate the HR and 95%CI, and information to estimate the OR in the analysis of clinicopathological features. The qualities of these studies were assessed using the Newcastle-Ottawa Quality Assessment Scale. HRs and ORs and their variance were calculated and pooled using Review Manager Version 5.2. RESULTS: A total of 24 studies were identified and comprised 3404 cases. β-catenin expression was significantly correlated with poor overall survival (OS) in GC patients (HR = 1.85, 95%CI: 1.39-2.46), but showed a significant degree of heterogeneity (I (2) = 71%, P < 0.0001). Subgroup analysis indicated that an abnormal pattern of β-catenin expression had an unfavorable effect on OS (HR = 1.79, 95%CI: 1.39-2.32). However, accumulation in the nucleus or loss of membrane did not influence the survival of GC patients independently. Moreover, the combined OR of β-catenin indicated that β-catenin expression was associated with Lauren classification (OR = 1.98, 95%CI: 1.19-3.29), lymph node metastasis (OR = 2.00, 95%CI: 1.44-2.77), distant metastasis (OR = 2.69, 95%CI: 1.35-5.38) and grade of differentiation (OR = 2.68, 95%CI: 1.66-4.34). β-catenin expression did not correlate with TNM stage (OR = 1.34 95%CI: 0.96-1.86), the depth of invasion (OR = 1.48, 95%CI: 0.94-2.33) or vascular invasion (OR = 1.11, 95%CI: 0.70-1.76). CONCLUSION: Abnormal β-catenin immunohistochemical expression may be associated with tumor progression and could be a predictive factor of poor prognosis in patients with GC.
AIM: To evaluate the effect of β-catenin immunohistochemical expression on the prognosis of gastric cancer (GC). METHODS: We searched Pubmed and Embase to identify eligible studies. The search ended on November 10, 2013, with no lower date limit. The citation lists associated with the studies were used to identify additional eligible studies. We included studies reporting sufficient information to estimate the HR and 95%CI, and information to estimate the OR in the analysis of clinicopathological features. The qualities of these studies were assessed using the Newcastle-Ottawa Quality Assessment Scale. HRs and ORs and their variance were calculated and pooled using Review Manager Version 5.2. RESULTS: A total of 24 studies were identified and comprised 3404 cases. β-catenin expression was significantly correlated with poor overall survival (OS) in GC patients (HR = 1.85, 95%CI: 1.39-2.46), but showed a significant degree of heterogeneity (I (2) = 71%, P < 0.0001). Subgroup analysis indicated that an abnormal pattern of β-catenin expression had an unfavorable effect on OS (HR = 1.79, 95%CI: 1.39-2.32). However, accumulation in the nucleus or loss of membrane did not influence the survival of GC patients independently. Moreover, the combined OR of β-catenin indicated that β-catenin expression was associated with Lauren classification (OR = 1.98, 95%CI: 1.19-3.29), lymph node metastasis (OR = 2.00, 95%CI: 1.44-2.77), distant metastasis (OR = 2.69, 95%CI: 1.35-5.38) and grade of differentiation (OR = 2.68, 95%CI: 1.66-4.34). β-catenin expression did not correlate with TNM stage (OR = 1.34 95%CI: 0.96-1.86), the depth of invasion (OR = 1.48, 95%CI: 0.94-2.33) or vascular invasion (OR = 1.11, 95%CI: 0.70-1.76). CONCLUSION: Abnormal β-catenin immunohistochemical expression may be associated with tumor progression and could be a predictive factor of poor prognosis in patients with GC.
Authors: María Sereno; Javier De Castro; Paloma Cejas; Miguel Angel García-Cabezas; Cristóbal Belda; Enrique Casado; Jaime Feliu; César Gómez; Miriam López; Manuel González Barón Journal: J Gastrointest Cancer Date: 2012-06
Authors: Bomi Kim; Sun-Ju Byun; Young A Kim; Ji Eun Kim; Byung Lan Lee; Woo Ho Kim; Mee Soo Chang Journal: Pathology Date: 2010-01 Impact factor: 5.306
Authors: N Murata-Kamiya; Y Kurashima; Y Teishikata; Y Yamahashi; Y Saito; H Higashi; H Aburatani; T Akiyama; R M Peek; T Azuma; M Hatakeyama Journal: Oncogene Date: 2007-01-22 Impact factor: 9.867
Authors: Jiajia Jin; Ping Zhan; Masaru Katoh; Susumu S Kobayashi; Kevin Phan; Hong Qian; Huijuan Li; Xiaoxia Wang; Xihua Wang; Yong Song Journal: Transl Lung Cancer Res Date: 2017-02
Authors: Lu Liu; Qiaoming Zhi; Meng Shen; Fei-Ran Gong; Binhua P Zhou; Lian Lian; Bairong Shen; Kai Chen; Weiming Duan; Meng-Yao Wu; Min Tao; Wei Li Journal: Oncotarget Date: 2016-07-26
Authors: Dong Won Baek; Byung Woog Kang; Soyoon Hwang; Jong Gwang Kim; An Na Seo; Han Ik Bae; Oh Kyoung Kwon; Seung Soo Lee; Ho Young Chung; Wansik Yu Journal: Chonnam Med J Date: 2017-05-25
Authors: Jan Bornschein; Jessica Nielitz; Ignat Drozdov; Michael Selgrad; Thomas Wex; Doerthe Jechorek; Alexander Link; Michael Vieth; Peter Malfertheiner Journal: Cancer Med Date: 2016-01-18 Impact factor: 4.452
Authors: A Marcell Szász; András Lánczky; Ádám Nagy; Susann Förster; Kim Hark; Jeffrey E Green; Alex Boussioutas; Rita Busuttil; András Szabó; Balázs Győrffy Journal: Oncotarget Date: 2016-08-02